Drug Discovery & Development 2023

ATCC is the premier global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While ... maintaining traditional collection materials, ATCC develops high quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Sino Biological, Inc. is a global leader in manufacturing affordable, high-quality reagents, including recombinant proteins, antibodies and cDNA clones-all in-house. We provide a one-stop shop for researchers and pharmaceutical companies around the world, helping our customers ... obtain the best reagents in the needed amounts to accelerate the pace of discovery and improve human health.

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications ... NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and ... quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.

For over 30 years, Miltenyi Biotec has been a leader in the development of products that empower the advancement of biomedical research and enable cell and gene therapy. We provide innovative tools to help with your sample preparation, cell isolation, cell culture, and cell ... analysis needs. Our solutions are designed to support everything from basic research to translational research and clinical application for immunology, stem cell biology, neuroscience, and cancer.

Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community - and through that, we aim to accelerate access to better health for people everywhere.

At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic ... and proteomic research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience.

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological ... samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

Despite incredible therapeutic innovations, the process for manufacturing these life-changing drugs lagged behind. ‍ Because of the largely paper-based processes involved in pharma manufacturing, millions of dollars were lost in drug batches due to quality deviations. These ... legacy processes just weren't going to hold up to the demands of new therapies - biologics, cell, and gene. ‍ We created Apprentice to bring the pharma industry up to speed with the transformative potential of technology. ‍ By bringing together co-founder Angelo Stracquantanio from the world of tech with fellow co-founders Gary Pignata and Alexandra Buttke from pharma, we're developing expeditious ways to create medicines that will forever make life better for the people who need them most - patients.